Dr. Ramon Coronado is CEO of Pelican Therapeutics, a subsidiary of Heat Biologics. He previously founded and has successfully served as CEO for other biopharma companies in the cellular and biologics therapeutic industry.
Dr. Ramon Coronado obtained his Polymer Engineering degree from the Simon Bolivar University in Caracas, Venezuela, where he developed a novel thermosensitive hydrogel biomaterial for medical applications; he then obtained his Master and Ph.D. in Biomedical Engineering at the University of Texas at San Antonio, UT Health San Antonio while working at U.S. Army Institute of Surgical Research in San Antonio, Texas. His graduate work and business beginnings were focused on Mesenchymal Stem Cells and immunoregulatory biological therapeutics. He has filed various patents in the biotech field and currently holds adjunct assistant professor positions at Ut Health San Antonio and Baylor College of Medicine.
Dr. Coronado brings over 15 years of experience in the biotech industry, including corporate and business development, management, biologics/cell therapeutics, clinical trials experience, and goal-oriented entrepreneurship.
George Peoples, MD, FACS
Chief Medical Officer
U.S. Army, COL (ret) George E. Peoples, MD, FACS, serves as CMO for both Heat Biologics and its subsidiary, Pelican Therapeutics. Dr. Peoples is currently professor of surgery at Uniformed Services University of the Health Sciences, as well as adjunct professor of surgical oncology at MD Anderson Cancer Center (MDACC). He is also the founder and director of Cancer Insight, LLC, a clinical research and development organization dedicated to the discovering, development and testing for emerging biotechnologies specializing in cancer immunotherapy.
Dr. Peoples recently retired from 30 years of active duty as a surgeon and as a research scientist in the military. He is the past chair of the cancer program at the San Antonio Military Medical Center, and the past deputy director of the United States Military Cancer Institute. Prior to that, he served as chief of surgical oncology at Walter Reed Amy Medical Center (WRAMC), as well as SAMMC. He is a graduate of the United States Military Academy, West Point and Johns Hopkins School of Medicine.
Dr. Peoples completed his surgical training at Harvard's Brigham and Women's Hospital, and during that time, also completed a post-doctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC. Dr. Peoples has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts and book chapters.
Matthew M. Seavey, Ph.D.
Matthew Seavey holds over a decade of preclinical drug development experience. Originally trained as an immunologist, Dr. Seavey is an expert in early drug development and has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas, including GI, CNS, immuno-oncology, respiratory, inflammation and cardio-metabolics. He has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, and Oncology Program Director at United Therapeutics. Dr. Seavey is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and founding of Oncoceutics. Most recently, Dr. Seavey served as Director of Preclinical Pharmacology for CinRx Pharma and founding partner of BioPoint Consulting, LLC. Dr. Seavey holds a B.S. in Microbiology from the University of Vermont, an M.Sc. and Ph.D. in Immunology from the University of Rochester, and an M.B.A. from West Chester University.